Review
The Journal of the Korean Rheumatism Association 2003; 10(2): 101-110
Published online June 30, 2003
© Korean College of Rheumatology
베체트병의 치료
장현규
단국대학교 의과대학 내과학교실
Behcet's disease is a chronic inflammatory disease with various organ involvements, its pathogenesis being unclear. It runs the clinical course of unpredictable exacerbations and remissions. In addition to a triple syndrome of oral ulceration, genital ulceration, and uveitis, there may be the involvement of other systems, such as joints, gastrointestinal tract, central nervous system, vessels, heart, or lungs. Although we have more information about the agents, through the controlled studies, that have been already available to us, the considerable portions of managements have been still done empirically. In addition, the major goal of treatment is to suppress an inflammatory status of the disease and therapy should be tailored according to the disease activity and involved organ. In these days, promising data have also been accumulated in the tumor necrosis factor inhibitors, especially in Behcet's patients with severe manifestations refractory to conventional treatments.
Keywords Behcet's disease, Treatment
PDF
Standard view
Export citation
Share Article
Review
The Journal of the Korean Rheumatism Association 2003; 10(2): 101-110
Published online June 30, 2003
Copyright © Korean College of Rheumatology.
베체트병의 치료
장현규
단국대학교 의과대학 내과학교실
Treatment of Behcet's Disease
Hyun Kyu Chang, M.D.
Department of Internal Medicine, College of Medicine, Dankook University, Cheonan, Korea
Correspondence to:Hyun Kyu Chang
Abstract
Behcet's disease is a chronic inflammatory disease with various organ involvements, its pathogenesis being unclear. It runs the clinical course of unpredictable exacerbations and remissions. In addition to a triple syndrome of oral ulceration, genital ulceration, and uveitis, there may be the involvement of other systems, such as joints, gastrointestinal tract, central nervous system, vessels, heart, or lungs. Although we have more information about the agents, through the controlled studies, that have been already available to us, the considerable portions of managements have been still done empirically. In addition, the major goal of treatment is to suppress an inflammatory status of the disease and therapy should be tailored according to the disease activity and involved organ. In these days, promising data have also been accumulated in the tumor necrosis factor inhibitors, especially in Behcet's patients with severe manifestations refractory to conventional treatments.
Keywords: Behcet's disease, Treatment
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Korean treatment recommendations for patients with axial spondyloarthritis
Mi Ryoung Seo, M.D., Jina Yeo, M.D., Jun Won Park, M.D., Yeon-Ah Lee, M.D., Ph.D., Ju Ho Lee, M.D., Eun Ha Kang, M.D., Ph.D., Seon Mi Ji, M.D., Ph.D., Seong-Ryul Kwon, M.D., Ph.D., Seong-Kyu Kim, M.D., Ph.D., Tae-Jong Kim, M.D., Ph.D., Tae-Hwan Kim, M.D., Ph.D., Hye Won Kim, M.D., Ph.D., Min-Chan Park, M.D., Ph.D., Kichul Shin, M.D., Ph.D., Sang-Hoon Lee, M.D., Ph.D., Eun Young Lee, M.D., Ph.D., Hoon Suk Cha, M.D., Ph.D., Seung Cheol Shim, M.D., Ph.D., Youngim Yoon, RN, Seung Ho Lee, Jun Hong Lim, Han Joo Baek, M.D., Ph.D.; on behalf of the Korean Society of Spondyloarthritis Research
J Rheum Dis 2023; 30(3): 151-169 -
Korean guidelines for the management of gout
Jennifer Jooha Lee, M.D., Ph.D., Ji Soo Lee, M.D., Ph.D., Min Kyung Chung, M.D., Ph.D., Joong Kyong Ahn, M.D., Ph.D., Hyo-Jin Choi, M.D., Ph.D., Seung-Jae Hong, M.D., Ph.D., Chong-Hyeon Yoon, M.D., Ph.D., Su-Hyun Kim, M.D., Ph.D., Kyung-Hwan Jeong, M.D., Ph.D., Jong-Woo Kim, M.D., Bo-Yeon Kim, M.D., Ph.D., Jin-Ho Shin, M.D., Ph.D., Woo Gyu Kim, M.D., Soo-Young Kim, M.D., Ph.D., Hyun-Jung Kim, Ph.D., Jeong-Soo Song, M.D., Ph.D., Jae-Bum Jun, M.D., Ph.D., Hyun-Ah Park, M.D., Ph.D., Shung Chull Chae, M.D., Ph.D., Bum Soon Choi, M.D., Ph.D., Tae Nyun Kim, M.D., Ph.D., Hyun Ah Kim, M.D., Ph.D.
J Rheum Dis 2023; 30(3): 141-150 -
Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean
Joong Kyong Ahn, M.D., Ph.D.
J Rheum Dis 2023; 30(2): 88-98
